Dupixent carries more of the load
- Dupixent is the center of the bull case after 31% constant currency sales growth in Q1 2026.
- The U.S. EYLEA franchise is under pressure, with legacy EYLEA down 36% year over year in Q1 2026.
- EYLEA HD is growing fast, but its $468 million in Q1 U.S. sales did not fully offset the older product decline.
- Fianlimab plus Libtayo missed its Phase 3 melanoma goal, removing a major near-term pipeline hope.
- Finn's view is balanced: strong finances and Dupixent growth, but weaker pipeline sentiment and EYLEA risk.
A stronger core, a thinner pipeline
Regeneron still has a real growth engine. Dupixent, sold with Sanofi, reached $4.9 billion in global Q1 2026 net sales and grew 31% on a constant currency basis. That is a huge base still growing quickly. It gives the company room to absorb pain in eye drugs.
The main pressure point is EYLEA. Combined U.S. EYLEA HD and EYLEA sales were $942 million in Q1 2026, down from $1.043 billion a year earlier. EYLEA HD grew 52% year over year, but legacy EYLEA fell 36% as patients moved to HD and competitors gained ground. Management also guided for another mid to high teens demand decline for legacy EYLEA in Q2.
The biggest thesis change is the fianlimab setback. The Phase 3 study of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint. That removes a possible multi-billion dollar cancer drug from the near-term bull case and makes Regeneron more dependent on Dupixent lasting longer.
The stock is not a clean bargain story or a broken story. The company has strong financial health, real cash generation, and Libtayo grew 54% year over year to $438 million in Q1. But the next leg now depends on Dupixent durability, EYLEA HD defense, and whether assets like garetosmab and cemdisiran can fill the pipeline gap.
Science, sales, and partners
Regeneron is a fully integrated biotech company. That means it discovers drugs, tests them, makes them, and sells some of them itself. Its research engine uses antibody discovery tools such as VelocImmune to create new drug candidates.
Money comes from two main places. First, Regeneron records direct product sales, such as U.S. EYLEA, EYLEA HD, Libtayo, Praluent, Evkeeza, and newer products. In Q1 2026, total net product sales were $1.535 billion.
Second, Regeneron earns collaboration revenue from partners. Sanofi is the most important partner because it records Dupixent sales and shares profits with Regeneron. Bayer records EYLEA sales outside the United States and shares profits with Regeneron. In Q1 2026, Sanofi collaboration revenue was $1.605 billion and Bayer collaboration revenue was $287 million.
This model works when the science keeps producing big products and partners keep selling well. It breaks when a key drug faces biosimilars, when a trial fails, or when a contract manufacturer delays an important product form like the EYLEA HD pre-filled syringe.
The drugs that matter
Dupixent
Dupixent treats allergic and inflammatory diseases, including atopic dermatitis, asthma, nasal polyps, COPD, and other conditions. Sanofi records sales, while Regeneron earns its share of the profits.
EYLEA HD and EYLEA
These eye drugs treat diseases such as wet age-related macular degeneration and diabetic macular edema. EYLEA HD is growing, but legacy EYLEA is falling because of competition, biosimilars, pricing pressure, and patient switching.
Libtayo
Libtayo is a cancer drug used in non-small cell lung cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, and other settings. Regeneron records global net product sales, which grew 54% year over year in Q1 2026.
Praluent
Praluent lowers LDL cholesterol. Regeneron handles the U.S. market, while Sanofi handles sales outside the United States and pays Regeneron royalties.
Kevzara and Evkeeza
Kevzara treats rheumatoid arthritis and other inflammatory diseases through the Sanofi partnership. Evkeeza treats homozygous familial hypercholesterolemia, a rare inherited cholesterol disorder.
Garetosmab, cemdisiran, and other pipeline drugs
These are pipeline assets that could matter over the next few years. Near-term watch points include garetosmab in FOP, cemdisiran in myasthenia gravis, and cemdisiran plus pozelimab in PNH.
Revenue split, not operating segments
Regeneron reports one operating segment. The mix below uses Q1 2026 revenue lines from the 10-Q, so it shows where reported revenue came from, not separate business units.
What could go wrong
Dupixent concentration
High impact · Medium oddsThe bull case leans heavily on Dupixent. It is growing quickly and has many approved uses, but that also means any slowdown would be felt across the whole company. Regeneron's Sanofi collaboration revenue is now the largest revenue line.
EYLEA erosion gets worse
High impact · High oddsLegacy EYLEA U.S. sales fell 36% year over year in Q1 2026. EYLEA HD grew, but the combined U.S. franchise still declined 10% year over year in the 10-Q table. More biosimilars expected in the second half of 2026 could push demand and price lower.
Pipeline gap after fianlimab
High impact · Medium oddsThe fianlimab plus Libtayo Phase 3 melanoma study failed to meet its primary endpoint. That makes the post-Dupixent pipeline look less certain. Regeneron still has many programs, but the next multi-billion dollar product is not obvious today.
Pre-filled syringe manufacturing delays
Medium impact · Medium oddsEYLEA HD pre-filled syringe applications depend on third-party fillers. Prior FDA inspection issues at Catalent already caused delays. A pre-filled syringe would not fix EYLEA competition, but it would make EYLEA HD easier for doctors to use.
Manufacturing margin pressure
Medium impact · Medium oddsA temporary interruption at the Limerick, Ireland facility hurt Q1 2026 gross margin on net product sales. Management said supply was not expected to be affected, but margins would stay pressured until production returned to normal. This matters because biotech profits depend on reliable high-margin manufacturing.